MedPath

A randomized, controlled, open, multi-center clinical study on the effectiveness and safety of Kangai injection in the treatment of cancer-induced fatigue

Phase 4
Recruiting
Conditions
Tumor patients (lung cancer, rectal cancer, malignant lymphoma, gynecological malignancy)
Registration Number
ITMCTR2100004974
Lead Sponsor
Jiangsu Provincial Hospital of Traditional Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1. Determined by histopathology or cytology as a tumor patient (lung cancer, rectal cancer, malignant lymphoma, gynecological malignant tumor);
2. Patients receiving chemotherapy;
3. ECOG score 0-1 points;
4. Meet the diagnostic criteria for cancer-related fatigue, and have a fatigue score >=4 (using a 0-10 numerical scale to score the degree of fatigue, 0 = no fatigue, 10 = the most severe fatigue);
5. Age from 18 to 80 years old;
6. Voluntarily sign written informed consent.

Exclusion Criteria

1. People with severe mental disorders;
2. People with speech and cognitive impairment;
3. People with allergies or known to be allergic to the drugs and their ingredients used in this test;
4. Patients with abnormal liver and kidney function indexes (ALT, AST, Scr exceed the upper limit of the normal reference range by 1.5 times);
5. Pregnant and lactating women, or women of childbearing age whose blood and/or urine HCG test results are positive before the test;
6. Patients with poor compliance;
7. Other patients who the investigator thinks are not suitable for enrollment.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Piper Fatigue Scale;
Secondary Outcome Measures
NameTimeMethod
KPS score;Immune function;Quality of life (EORTC-QLQ-C30);Peripheral blood;Incidence of side effects of chemotherapy;
© Copyright 2025. All Rights Reserved by MedPath